In response to injury, the brain produces different neuroprotective molecules, such as insulin-like growth factor I (IGF-I). However, IGF-I is also taken up by the brain from the circulation in response to physiological stimuli. Herein, we analyzed in mice the relative contribution of circulating and locally produced IGF-I to increased brain IGF-I levels after insult. Traumatic brain injury (TBI) induced by a controlled impact resulted in increased IGF-I levels in the vicinity of the lesion, but mice with low serum IGF-I showed significantly lower increases. Indeed, in normal mice, peripheral IGF-I accumulated at the lesion site after injury, and at the same time serum IGF-I levels decreased. Collectively, these data suggest that serum IGF-I enter into the brain after TBI and contributes to increased brain IGF-I levels at the injury site. This connection between central and circulating IGF-I provides an amenable route for treatment, as subcutaneous administration of IGF-I to TBI mice led to functional recovery. These latter results add further support to the use of systemic IGF-I or its mimetics for treatment of brain injuries.
Introduction
The brain produces its own repertoire of hormones and growth factors. Many, if not all of them, are also produced by peripheral tissues. Probably the best studied among them are neurosteroids, locally produced gonadal hormones with a profound impact on brain physiology (Balthazart and Ball 2006) . This functional arrangement poses the question of the significance of brain hormones produced also by peripheral organs on brain function. While for neurosteroids it is already recognized that gonadalderived steroids play numerous actions in the brain (Arevalo et al. 2015) , much less is known about the role of other peripheral hormones. In recent years, we have determined that circulating insulin-like growth factor I (IGF-I) plays an active role in brain function (Fernandez and Torres-Aleman 2012) , but its possible interplay with locally produced IGF-I remains poorly characterized.
There is already evidence from a variety of studies suggesting that brain IGF-I and peripheral IGF-I interact with each other. Thus, increases in brain activity after physiological stimuli such as environmental enrichment elicit increased serum IGF-I input to the brain (Guzzetta et al. 2009; Nishijima et al. 2010 ) together with increased IGF-I levels in specific brain cells (Ziv et al. 2006; Ciucci et al. 2007) . Similarly, increased brain IGF-I in response to injury, reflects enhanced IGF-I expression (Lee et al. 1992; Guan et al. 2003; Madathil et al. 2010 ), but probably also increased uptake of serum IGF-I by brain vessels (Beilharz et al. 1998; Lopez-Lopez et al. 2004 ). Furthermore, the brain adapts to changes in peripheral IGF-I (Mitschelen et al. 2011; Trueba-Saiz et al. 2016) , and vice versa, serum IGF-I levels are influenced in part by brain IGF-I function. For example, deafferentation of the cerebellum in rats induces parallel changes in cerebellar and serum IGF-I (Fernandez et al. 1998) . From a practical point of view, this dialog between serum and brain IGF-I may be of therapeutic utility as serum IGF-I levels have been proposed to predict clinical outcome after brain injuries (De Smedt et al. 2011; Mattlage et al. 2016 ) and systemic administration of IGF-I is beneficial for a variety of brain conditions (Torres Aleman 2012).
In the present study, we analyzed whether circulating IGF-I participates in the response to brain damage, using traumatic brain injury (TBI) as a model that is, unfortunately, very common in the clinical setting (Coronado et al. 2015) . We observed that local increases in brain IGF-I after injury are partially due to enhanced entrance of circulating IGF-I, which provides strong support for a therapeutic use of systemic administration of IGF-I after brain injury.
Methods

Animals
Adult male C56BL/6 (28-35 g) and liver IGF-I deficient (LID) mice from the Cajal Institute were housed in standard cages (48 × 26 cm 2 ) with 5 mice per cage. Mice were maintained on a lightdark cycle (12-12 h, lights on at 8 AM) at constant temperature (22°C) and humidity, and with food (pellet rodent diet) and water ad libitum. All experimental protocols were performed during the light cycle. Animal procedures followed European guidelines (86/609/EEC, European Council Directives) and were approved by the local Bioethics Committee.
Controlled Cortical Injury
Mild Controlled Cortical Injury (CCI) was induced using an electromagnetic stereotaxic impactor (Impact One, MyNeuroLab, Leica), as described (Brody et al. 2007) . Mice were anesthetized with isofluorane (induction at 4% and maintenance at 2%) administered through a nose mask (David Kopf Instruments). Anesthesia was monitored by assessing pedal withdrawal reflexes. Animals were placed on a digital stereotaxic frame (Stoelting Co) with cup head holders (David Kopf Instruments). Temperature was maintained with a custom-made heating bed. In order to protect vision, Vaseline was applied to their eyes. All tools were clean with ethanol. The skin was scrubbed with Betadine, and the top of the skull was exposed with a 1 cm skin incision. A craniotomy was performed using a 5 mm trephine (Fine Science Tools). The right edge of the impactor tip (3 mm) was aligned with the midline suture and the posterior edge of the tip with the horizontal anterior portion of the bregma suture using the stereotaxic arm. The tip was positioned over the left parieto-temporal cortex (−1.0 mm bregma and 2.5 mm left to midline). The zero depth position was determined by aligning the tip of the impact device in the down position with the surface of the dura. When contact was made, the impactor tip was retracted and lowered 1 mm before inducing impact (speed: 3.6 m/s dweel: 100 ms). The surface of the dura was cleaned and dried with room-temperature sterile saline and dry cotton. A 6 mm-diameter plastic disc was glued with cyanoacrylate to the skull to cover the craniotomy. The skin was closed with 4 discontinuous sterile 5-0 braided silk sutures (Lorca Marin). Sham injury consisted of exposure to anesthesia, stereotaxic mounting, skin and fascia reflection, craniotomy and incision closing with sutures. A group of TBI animals were also implanted during surgery with an osmotic mini-pump for chronic administration of either IGF-I (n = 15) or vehicle (n = 7; see below). Results showed no significant differences between CCI injured animals (n = 10) and CCI injured animals with vehicle treatment, so they were pulled together. One of the CCI injured animals had seizures after the surgery and was euthanized. The naïve, sham and injured animals for the rest of the assays and time points will be described in the corresponding figure legends.
IGF-I Administration
Chronic subcutaneous administration of hIGF-I (Pre-Protech; 50 μg/kg/day) and vehicle (saline) was performed using Alzet osmotic mini-pumps (Model 1004, 28 days infusion, USA) following the manufacturer's instructions. Pumps were surgically implanted under the skin between the scapulae immediately after the TBI procedure. For monitoring the entrance of peripheral IGF-I, either vehicle (saline) or biotinylated human IGF-I (150 μg/kg) were injected intraperitoneally 7 days after surgery (sham or CCI). One hour after the injection, animals were sacrificed.
Blood-Brain Barrier Integrity Assay
To test the permeability of the Blood-Brain Barrier (BBB), injured animals were injected at different times after the lesion in the lateral vein of the tail with 200 μL of a 2% solution of Evans Blue (Sigma, E2129) prepared in PBS and compared with sham-injured mice. Animals were perfused 1 h after the injection and their brains inspected for the presence of dye staining. Evans Blue staining was observed in animals injected 1 and 4 days after injury whereas the mice injected 7 days after TBI did not show any staining ( Supplementary Fig. 1 ). The injured hemispheres were then homogenized in 1 mL of a 50% Trichloroacetic acid solution and centrifuged at 10 000 × g for 30 min. The supernatants were collected and Evans Blue was quantified by absorbance at 620 nm using a fluorescence microplate reader (Fluostar Optima, BMG) according to a standard curve.
Adhesive Removal Test
The adhesive removal test was used to assess long-term sensorimotor deficits following TBI, as described (Bouet et al. 2009 ), with slight modifications. During the first week mice were habituated to the experimental room for 1 h. Then, they were removed from their home cages, handled, and placed 120 s in the testing box for habituation. After this acclimation period, animal cages were taken to the behavioral room 1 h before starting the experiment. Each mouse was handled by the scruff of the neck with one hand, in order to immobilize its head and forepaws. Subsequently, 2 adhesive tape strips (0.3 cm × 0.4 cm) were applied with equal pressure on each animal paw, switching the placement order (right or left) randomly within each group. Once the adhesive tape strips had been placed, mice were introduced in the testing box until they had removed both tape strips, and for a maximum duration of 120 s. This procedure was repeated until there was no asymmetry on the time to remove the adhesive from each animal forepaw's, and no significant differences between experimental groups were found. When all animals reached a "plateau", they underwent surgery, and they were re-tested at the adhesive removal test once weekly for a 28 days period. A camera placed under the testing box allowed video-recording of each trial. Behavioral observations were carried out by an investigator blind to the experimental conditions. In order to analyze the magnitude of asymmetry, time-to-remove the tape from the ipsilateral limb was subtracted from the time-to-remove the tape from the contralateral limb (see accompanying Supplementary Video 1).
Blood and Tissue Collection
Blood was collected from the submandibular vein to obtain blood with minimal pain or distress. Using a method described elsewhere (Golde et al. 2005) , 0.09-0.05 mL of blood was obtained with a sterile lancet (Sofolix, Braun) from each mouse before surgery, and then, once weekly for the 28 days period that lasted the experiment. All samples were stored at −20°C until the ELISA was performed. For tissue collection, animals were anaesthetized with pentobarbital (50 mg/kg, ip) and then perfused transcardially with saline buffer 0.9%. Liver and brain were removed, and peri-lesion cortex was dissected and frozen immediately in dry ice. Samples were stored at −80°C until ELISA or qPCR were performed. For immunohistochemistry and in situ hybridization, animals were perfused with saline buffer. Brains were then sucrose cryoprotected and frozen for in situ hybridization, or animals were perfused with 4% paraformaldehyde dissolved in phosphate buffer (pH 7.4) for inmunohistochemistry.
IGF-I ELISA
IGF-I in serum and tissue was determined using a mousespecific ELISA (R&D Systems), as described (Trejo et al. 2007 ). Frozen tissue samples were homogenized in 1 N acetic acid/4°C, boiled for 20 min to eliminate the interference with IGF-binding proteins, and frozen at −80°C for 1 h. Frozen protein extract was lyophilized overnight and resuspended in PBS in the minimal volume necessary to analyze IGF-I content in duplicate and total protein content, by BCA, in triplicate.
Fluorescent In Situ Hybridization
Brain slices were sectioned with a cryostat (Leica) at 10 μm. Fluorescence in situ hybridization was performed using custom Stellaris FISH Probes. The set comprised 48 single-labeled oligonucleotides (see Supplementary Table) designed to bind the Mus Musculus IGF-I mRNA by utilizing the Stellaris FISH Probe Designer (Biosearch Technologies, Inc.). Following the manufacturer's instructions, brain slices were hybridized with the IGF-I mRNA Stellaris FISH Probe set, labeled with CAL Fluor Red 610 (Biosearch Technologies, Inc.). Photos were taken with a fluorescent microscope (Leica) following manufacturer's instructions.
Immunohistochemistry
Coronal brain sections of 50 μm were obtained on a vibrating blade microtome (Leica VT 1000S) right after fixation. Both the cryo-sections, used for in situ hybridization, and the vibratome slices followed the same immunostaining protocol. Sections were immersed 3 times in PBS-Triton X-100 (0.2%), and then blocked with normal donkey serum for 2 h. Next, slices were incubated overnight with specific primary antisera. Antibodies used included an in-house anti-mouse IGF-I made in rabbit (1:100 dilution, see Carro et al. 2000) , anti-mouse Iba1 made in goat (1:100 dilution; Novus ND100-1028), or in rabbit (1:1000; Wako Cat.#019-19741), anti-mouse GFAP made in mouse (1:1000; Sigma G3893) or in rabbit (1:1000; Dako Z0334), and anti-mouse NeuN made in mouse (1:1000; Millipore MAB377). Donkey antirabbit IgG (H+L) Alexa Fluor 488 conjugate (Thermo Fisher Scientific, A-21206), donkey anti-mouse IgG (H+L) Alexa Fluor 594 conjugate (Thermo Fisher Scientific, A-21203) and donkey anti-goat IgG (H+L) Alexa Fluor 647 (Thermo Fisher Scientific, A-21447) were used as secondary antibodies. Donkey serum was used as a negative control in place of primary antibodies on adjacent sections. Streptavidin Alexa Fluor 488 conjugate (Life Technologies S-32354) was used against biotinylated IGF-I. Photos were taken with a confocal microscopy (Leica).
RNA Extraction, Reverse Transcription, and Duplex Real-time qPCR
Total RNA isolation from brain tissue was carried out with Trizol (Life Technologies). One microgram of RNA was reverse transcribed using High Capacity cDNA Reverse Transcription Kit (Life Technologies) according to the manufacturer's instructions and then assayed by qPCR or stored at −20°C until use. Of this, 62.5 ng of cDNA were amplified using TaqMan probes for IGF-I (FAM reporter, Mm00439560_m1), IGF-IR (FAM reporter, Mm00802831_m1) and 18S as endogenous control (VIC reporter, Life Technologies). Each sample was run in triplicate in 20 μL of reaction volume using TaqMan Universal PCR Master Mix according to the manufacturer's instructions (Life Technologies). All reactions were performed in a 7500 Real-Time Figure 1 . Early changes in brain IGF-I in response to injury. (A) IGF-I protein levels 1 day after TBI (n = 5) are increased in the peri-lesion zone as compared with naïve (n = 4) and sham-operated animals (n = 5). Sham mice also show a small increase in IGF-I compared with naïve. Two-way ANOVA showed an interaction between hemisphere and injury (F (2, 22) = 168.8, P < 0.0001). (B) Expression of IGF-I mRNA is increased at the lesion site early after TBI (1 day). A significant interaction between hemisphere and injury was found after performing a 2-way ANOVA (F (2, 30) = 6.235, P = 0.005; n = 6 naïve; n = 5 sham; n = 8 injured). (C) TBI animals (n = 5) have an increased expression of IGF-I receptor (IGF-IR) mRNA in the peri-injury site compared with naïve animals (n = 5). Two-way ANOVA indicates a significant effect of injury (F (2, 29) = 4.999, P = 0.014). No differences were observed in sham animals (n = 8). Asterisks represent post hoc comparisons; *P < 0.05, **P < 0.01, ***P < 0.001. CL and I abbreviations stand for contralateral and ipsilateral to injury, respectively.
PCR system (Life Technologies) with the following program: 2 min/50°C (1 cycle), 10 min/95°C (1 cycle), 15 s/95°C, and 1 min/ 60°C (40 cycles). Off-line analysis for the determination of relative mRNA quantity was conducted using a modified 2(−ΔΔCT) method as described (Pfaffl 2001) . Results depict fold increase of relative mRNA expression in experimental groups with respect to controls.
Statistical Analysis
Statistical analysis was performed using SPSS Statistics 22 (IBM) and GraphPad Prism six software. Student's t-test (for comparing 2 groups) or either 1-way or 2-way ANOVAs (for more than 2 groups) followed by Bonferroni's multiple comparison test as a post hoc were performed. Two-way ANOVA with repeated measures was used to analyze sensorimotor performance and serum IGF-I over time. Results are shown as mean ± standard error (SEM) and the P-values coded as: *P < 0.05, **P < 0.01, and ***P < 0.001.
Results
We first confirmed that brain IGF-I increased in our TBI model. Indeed, 24 h after injury, an increase in IGF-I protein and mRNA levels at the injury site was observed (Fig. 1A,B ). This increase lasted for at least 4 weeks (see Fig. 5B,C) . Sham-operated animals also show a transient increase of IGF-I protein at the surgery site, as compared with naïve animals. Additionally, a modest significant early increase in IGF-I receptor mRNA was observed at the injury site, as compared with naive mice (Fig. 1C ), but its levels normalized after 1 month ( Supplementary Fig. 1B) . At the cellular level, we also confirmed that increased IGF-I mRNA expression was seen in the vicinity of the lesion 3 days after injury in microglial cells (Iba1 + -cells, Fig. 2A ), astrocytes week after injury. (Fig. 2B) , and neurons (Fig. 2C) . One week after TBI, IGF-I immunoreactivity was still seen in these 3 types of brain cells (Fig. 3) .
To determine the possible contribution of circulating IGF-I to the observed increases in IGF-I protein at the injured site, mutant LID mice with very low levels of circulating IGF-I (Yakar et al. 1999 ) were submitted to TBI. Significantly lower increases in IGF-I protein at the injury site were observed in these mice, as compared with controls (Fig. 4A) . The moderate increased IGF-I protein seen in LID mice at the lesion side is likely due to increased local synthesis, as a modest increase in IGF-I mRNA expression was observed ( Fig. 4B ). Of note, basal levels of IGF-I in the cortex of LID mice were lower than controls (P < 0.001).
To further ascertain a role of circulating IGF-I in injuryinduced increases in the brain, we injected intraperitoneally biotin-labeled IGF-I to control mice 1 week after TBI. As shown in Fig. 4C , a marked biotin-IGF-I immunostaining was seen at the injury site as compared with sham-injured mice.
In human patients, where IGF-I brain levels after injury cannot be determined, it has been reported that serum IGF-I levels are frequently reduced after TBI (Wagner et al. 2010) . We found similarly decreased serum IGF-I after TBI in mice (Fig. 4D) . Importantly, LID mice did not show any further decreases in serum IGF-I after TBI (Fig. 4D) . Because the liver is the main producer of serum IGF-I (Yakar et al. 1999) , we determined possible changes in liver IGF-I synthesis 1 week after TBI, but did not find any ( Supplementary Fig. 1C ).
Since both wild type (WT) and LID injured mice showed similar sensorimotor impairments for at least 1 month, as determined by the adhesive removal test that involves motor coordination with propioception ( Fig. 5A and Supplementary Video 1), we treated WT mice with a subcutaneous infusion of IGF-I using osmotic mini-pumps, and gradually, but fully, sensorimotor skills were restored after 4 weeks of treatment (Fig. 5A) . This confirms the beneficial effects of IGF-I seen in pilot studies in humans (Hatton et al. 1997) . Treatment of TBI mice with subcutaneous IGF-I did not modify already elevated IGF-I mRNA and protein levels at the injury site ( Fig. 5B,C) , nor it affected liver IGF-I mRNA ( Supplementary Fig. 1B) . Intriguingly, treatment of Interestingly, naïve LID mice have significantly less IGF-I in cortex compared with naïve WT (P < 0.001, not shown in the graph for clarity). Two-way ANOVA shows a significant interaction between hemisphere and experimental group (F(5, 52) = 5.882, P = 0.000; n = 5-8 per group). (B) LID mice showed a modest increase of IGF-I mRNA after injury compared with the contralateral hemisphere (t-test, P = 0.033 vs. contralateral; n = 11 per group). (C) WT injured animals injected with biotinylated hIGF-I (bIGF-I) 1 week after TBI show increased bIGF-I immunoreactivity at the injury site compared with sham animals injected with bIGF-I and to injured animals injected with saline (n = 2 per group). Representative micrographs are shown. Biotin was revealed with streptavidin (see methods). Bars represent 50 μm. (D)
Decreased serum IGF-I after TBI was found in both WT (n = 15) and WT + hIGF-I (n = 15) mice compared with WT naïve+sham (n = 10). LID animals with low serum IGF-I levels compared with WT naïve+sham, did not show any further decreases after TBI (n = 5-11). A significant interaction was found between time and injury in a repeated measures ANOVA (F (3, 168) = 3.083, P = 0.029 vs. naïve-sham). To reduce the number of animals and given that they showed no differences between them, naïve and sham animals were pooled together. Asterisks represent post hoc comparisons; ns, non-significant,*P < 0.05, **P < 0.01, ***P < 0.001. normal mice with human IGF-I for 1 month reduced endogenous (murine) brain IGF-I protein levels (Fig. 5B ).
Discussion
The present results indicate that circulating IGF-I participates in brain responses to injury. Thus, the dual origin of IGF-I in the brain, from the periphery and from local synthesis, cooperatively contributes to increase IGF-I levels after injury. The existence of a cooperative mechanism is supported by the modest increase in brain IGF-I levels seen after TBI in mutant LID mice with low serum IGF-I even though these animals maintain increased brain IGF-I mRNA expression at the injured side. Thus, reduced IGF-I protein levels probably originate from less available serum IGF-I in LID mice. In agreement with this possibility, we observed increased accumulation of systemically administered biotin-labeled IGF-I after TBI. Altogether these results suggest that a substantial part of the increased IGF-I content at the injury site originates from circulating IGF-I.
Because TBI abruptly disrupts BBB integrity, circulating IGF-I would initially enter freely into the brain. However, unless irreversible damage occurs, BBB integrity is rapidly repair after injury (Alluri et al. 2015) . For this reason, we injected labeled IGF-I 1 week after injury, when BBB integrity was already restored, as confirmed by the absence of Evans Blue staining in brain parenchyma ( Supplementary Fig. 1A) . Thus, peripheral IGF-I will likely enter the brain at this time after injury only through active transport (Nishijima et al. 2010) .
Importantly, in this TBI model, cooperation between peripheral and central IGF-I was not sufficient to restore function. Only when additional peripheral IGF-I was provided by exogenous administration, sensorimotor function was fully restored. As local levels remained elevated even after exogenous administration, it seems that higher amounts of IGF-I than those endogenously available are needed to restore function. Indeed, LID mice with low serum IGF-I show similar functional deficits than WT mice, further reinforcing the notion that endogenous serum levels in WT mice, that are much higher, still do not cover increased needs after injury. Previous observation showed that administration of exogenous IGF-I to LID mice also resulted in restored brain function, including synaptic plasticity, learning and memory, excitatory/inhibitory balance (Trejo et al. 2007) , and hippocampal adult neurogenesis (Trejo et al. 2008) . Therapeutically insufficient endogenous input of IGF-I may be related to development of resistance to this growth factor in the damaged brain (Garcia-Galloway et al. 2003) , but this possibility remains to be further explored.
Previous work showed that serum IGF-I has an important role in normal brain function. This includes such diverse actions as maintenance of cognitive skills, hippocampal size, or neuronal plasticity (Trejo et al. 2007 ). In turn, brain IGF-I acts as an activity-dependent growth factor involved in local modulation of synaptic activity, in a context-dependent manner (Gazit et al. 2016; Mardinly et al. 2016) . We recently reported that under normal circumstances, the entrance of serum IGF-I into the brain inhibits local IGF-I levels (Trueba-Saiz et al. 2016) , which accords with lower levels of brain IGF-I when additional exogenous IGF-I is administered. Similarly, our present results indicate that a cooperative/complementary activity of serum and brain IGF-I takes place in response to injury, as both sources of IGF-I seem to be involved in restoring brain function after insults. Whether these 2 sources fulfill specific reparative roles by targeting different cell types and/or events, needs further analysis. At any rate, IGF-I exerts wide-spectrum neuroprotection, including protection against inflammation and oxidative stress (Torres Aleman 2012), 2 major pathogenic mechanisms involved in TBI-induced neuronal death (Abdul-Muneer et al. 2015) .
An important observation is that serum IGF-I levels were reduced after TBI. This decrease was observed even in mice treated with exogenous IGF-I. Actually, IGF-I treated mice show a more pronounced decrease in serum IGF-I levels even though liver IGF-I mRNA expression remained unaffected. It is possible that the observed decrease is related to increased clearance of serum IGF-I, but more work is needed to clarify this observation. Because in IGF-I-treated mice brain accumulation of IGF-I after TBI was markedly enhanced (Fig. 5B) , it seems that treatment with IGF-I enhances brain uptake. Whether this stimulation is due to displacement from circulating serum IGF-binding proteins requires also further analysis.
Brain trauma has been reported to impair different neuroendocrine axes, including the GH/IGF-I somatotropic axis (Rosario et al. 2013; Tanriverdi et al. 2015) and lower serum IGF-I levels Both WT (n = 17) and LID (n = 11) mice submited to TBI showed sustained loss of sensorimotor function as measured with the adhesive removal test compared with naïve and sham animals (n = 18 WT and n = 8 LID). Treatment with IGF-I gradually restored sensorimotor function (n = 15). Repeated measures ANOVA showed a significant interaction between time and experimental group (F (14.21, 241.5) = 2.205, P = 0.008). Bonferroni test showed significant differences from 7 to 28 days after injury in WT injured ( @ P < 0.05, @@ P < 0.01) and LID injured animals (*P < 0.05, ***P < 0.001), and in WT TBI + hIGF-I at 7 days after TBI ( # P < 0.05). (B) After 28 days of injury, increased levels of IGF-I protein at the injured site in cortex were returning to normal in WT mice but WT mice treated with IGF-I still show a significant increase (n = 5-10). Three-way ANOVA showed a significant interaction between injury and hemisphere (F (1,42) = 4.665 = 0.037) and between injury and treatment (F (1,42) = 5.110 = 0.029). (C) However, increased IGF-I mRNA levels at the lesion site remained increased after 28 days in WT and WT-IGF-I groups. A significant interaction between injury and hemisphere was found by a 3-way ANOVA (F (1, 56) = 15.431, P < 0.000, n = 5-11 per group).
Asterisks represent post hoc comparisons; *P < 0.05, **P < 0.01, ***P < 0.001. have been found in infant rats after TBI (Ozdemir et al. 2012) . As the liver is the main producer of circulating IGF-I (Yakar et al. 1999) , reduced hepatic production of IGF-I could account for the observed decrease. However, no changes in liver IGF-I mRNA were seen after TBI, suggesting that injury-induced changes originate in brain. Thus, brain damage resulting in impaired neurological function may demand a continued IGF-I support from the periphery, acting as a "sink" for serum IGF-I. This interpretation is reinforced by the observation in humans of reduced circulating levels of another neurotrophic factor such as BDNF (Korley et al. 2016 ), suggesting the existence of a generalized increased demand for neurotrophic support in the injured brain. At any rate, our data indicate that endogenous serum IGF-I input is not sufficient to cope with an increased brain demand, and neurological function remains deteriorated. This latter explanation is based on the observation that peripheral administration of IGF-I restored neurological function after TBI. Interestingly, a pilot study performed decades ago showed that treatment of TBI patients with systemic IGF-I was beneficial (Hatton et al. 1997) , and more recent studies show that the closely related insulin may also be beneficial (Brabazon et al. 2017) . Pre-clinical studies confirmed positive actions of IGF-I therapy on functional recovery (Saatman et al. 1997; Rubovitch et al. 2010) .
Additional support for functionally meaningful changes in serum IGF-I levels after brain injury is provided by more recent clinical studies. Thus, high serum IGF-I levels immediately after stroke are associated to better outcomes (De Smedt et al. 2011 ). Further, lower levels of serum IGF-I during the first week after ischemia parallel shorter discharge time for the patients (Mattlage et al. 2016) . We speculate that these apparently disparate observations reflect that those patients with higher availability of serum IGF-I immediately after injury and are able to capture more circulating IGF-I (reflected as lower serum IGF-I) in the aftermath, will cope better with injury. However, this possibility would require further studies. In addition, recent in vitro studies suggest epileptogenic actions of prolonged IGF-I treatment after injury (Song et al. 2016) , which introduces a cautionary view to possible translation of IGF-I therapy into the clinic.
In summary, the present results suggest the existence of a functional cooperation between circulating and brain IGF-I, and provide further support for the therapeutic use of this growth factor, particularly when neurological impairment is accompanied by reduced serum IGF-I levels, as this is a clear indication of greater brain demand for IGF-I support. We may conclude that serum IGF-I constitutes an important determinant of IGF-I function after TBI. Since there is an intense search for biomarkers of TBI severity (Zetterberg et al. 2013) , altered levels of serum IGF-I (these findings and (Wagner et al. 2010; De Smedt et al. 2011; Mattlage et al. 2016) , together with other growth factors (Korley et al. 2016) , can be a useful indicator in the prognosis of the lesion and help in the decision to use IGF-I.
